title: Long term hematologic recovery after autologous stem cell transplantation in lymphoma patients: impact of the number of prefreeze and post-thaw CD34+ cells.
abstract: BACKGROUND
  Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cells is widely used as consolidation in lymphoma patients. The rapidity and stability of cell engraftment correlate with the number of CD34+ cells in the autograft. However, whether CD34+ cells should be quantified before or after cryopreservation remains unclear.
  
  
  METHODS
  Of 173 consecutive patients who underwent ASCT in our department from Nov 1, 1995 to Nov 1, 2000, 133 (78 %) were alive without relapse at one year. We report here the results for 106 patients whose hematologic data were available.
  
  
  RESULTS
  At one year, the hemoglobin was normal in 47% of the patients, the leukocytes, in 77% and the platelets, in 60%. Only 33% had a normal blood count. We observed a significant correlation between prefreeze and post-thaw CD34+ cell numbers (r = 0.77). However, multivariate analysis using the Cox model with smoothing splines to assess the best cut-off point for these numbers demonstrated that the only independent predictive factor for a normal blood count after one year was a prefreeze number of CD34+ cells above 5.10(6)/kg.
  
  
  CONCLUSIONS
  An optimal long-term hematologic recovery after ASCT required a number of prefreeze CD34+ cells of at least 5.10(6)/kg.
authors.affiliation: Institut universitaire d'hématologie, Hôpital Saint-Louis, Inserm ERM 0220, 1, avenue Claude-Vellefaux, 75010 Paris, France. nicolas.mounier@sls.ap-hop-paris.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Jérome
authors.initials: J
authors.lastname: Larghero
authors.forename: Julien
authors.initials: J
authors.lastname: Manson
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.forename: Isabelle
authors.initials: I
authors.lastname: Madelaine-Chambrin
authors.forename: Josette
authors.initials: J
authors.lastname: Brière
authors.forename: Marjane
authors.initials: M
authors.lastname: Ertault
authors.forename: Christophe
authors.initials: C
authors.lastname: Hennequin
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Miclea
authors.forename: Marc
authors.initials: M
authors.lastname: Benbunan
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Marolleau
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018952:Antigens, CD34; D001772:Blood Cell Count; D015925:Cryopreservation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction
chemical_list: D018952:Antigens, CD34